The decision to open proceedings also concerns a number of generic companies including Krka d.d., Lupin Limited, Matrix Laboratories Limited (subsidiary of Mylan Inc as of 28 August 2006), Niche Generics Limited (subsidiary of Unichem Laboratories Limited) and Teva UK Limited / Teva Pharmaceutical Industries Limited, as regards a number of individual, possibly restrictive, agreements between each of them and Servier.
Cette décision concerne également plusieurs fabricants de génériques, notamment Krka d.d., Lupin Limited, Matrix Laboratories Limited (filiale de Mylan Inc), Niche Generics Limited (filiale d’Unichem Laboratories Limited) et Teva Pharmaceutical Industries Limited, l'enquête ayant trait à plusieurs accords, potentiellement restrictifs, conclus entre chacun d'eux et Servier.